JP6501524B2 - Ｐｓｍａ上昇により致死性前立腺癌が同定される - Google Patents

Ｐｓｍａ上昇により致死性前立腺癌が同定される Download PDF

Info

Publication number
JP6501524B2
JP6501524B2 JP2014558737A JP2014558737A JP6501524B2 JP 6501524 B2 JP6501524 B2 JP 6501524B2 JP 2014558737 A JP2014558737 A JP 2014558737A JP 2014558737 A JP2014558737 A JP 2014558737A JP 6501524 B2 JP6501524 B2 JP 6501524B2
Authority
JP
Japan
Prior art keywords
psma
imaging
agent
expression
pet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014558737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015513083A (ja
JP2015513083A5 (enExample
Inventor
バンダー，ニール・エイチ
Original Assignee
コーネル ユニヴァーシティー
コーネル ユニヴァーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーネル ユニヴァーシティー, コーネル ユニヴァーシティー filed Critical コーネル ユニヴァーシティー
Publication of JP2015513083A publication Critical patent/JP2015513083A/ja
Publication of JP2015513083A5 publication Critical patent/JP2015513083A5/ja
Application granted granted Critical
Publication of JP6501524B2 publication Critical patent/JP6501524B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Reproductive Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
JP2014558737A 2012-02-24 2013-02-22 Ｐｓｍａ上昇により致死性前立腺癌が同定される Expired - Fee Related JP6501524B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261602900P 2012-02-24 2012-02-24
US61/602,900 2012-02-24
PCT/US2013/000045 WO2013126147A2 (en) 2012-02-24 2013-02-22 Elevated psma identifies lethal prostate cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019050913A Division JP2019144254A (ja) 2012-02-24 2019-03-19 Ｐｓｍａ上昇により致死性前立腺癌が同定される

Publications (3)

Publication Number Publication Date
JP2015513083A JP2015513083A (ja) 2015-04-30
JP2015513083A5 JP2015513083A5 (enExample) 2016-03-31
JP6501524B2 true JP6501524B2 (ja) 2019-04-17

Family

ID=49003541

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014558737A Expired - Fee Related JP6501524B2 (ja) 2012-02-24 2013-02-22 Ｐｓｍａ上昇により致死性前立腺癌が同定される
JP2019050913A Pending JP2019144254A (ja) 2012-02-24 2019-03-19 Ｐｓｍａ上昇により致死性前立腺癌が同定される

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019050913A Pending JP2019144254A (ja) 2012-02-24 2019-03-19 Ｐｓｍａ上昇により致死性前立腺癌が同定される

Country Status (6)

Country Link
US (2) US20130225541A1 (enExample)
EP (2) EP3064945A1 (enExample)
JP (2) JP6501524B2 (enExample)
CA (1) CA2865282A1 (enExample)
HK (1) HK1205788A1 (enExample)
WO (1) WO2013126147A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1202256A1 (en) * 2012-02-28 2015-09-25 Cornell University Psma as a biomarker for androgen activity in prostate cancer
US10340046B2 (en) 2016-10-27 2019-07-02 Progenics Pharmaceuticals, Inc. Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
CA3056261A1 (en) 2017-04-07 2018-10-11 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
US12602772B2 (en) 2018-01-08 2026-04-14 Progenics Pharmaceuticals, Inc. Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination
CN113272859B (zh) 2019-01-07 2025-04-04 西尼诊断公司 用于平台中立性全身图像分段的系统及方法
TWI872062B (zh) 2019-04-24 2025-02-11 美商普吉尼製藥公司 用於偵測轉移之骨掃描影像之自動及互動式分析系統、裝置及方法
US12417533B2 (en) 2019-09-27 2025-09-16 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US11900597B2 (en) 2019-09-27 2024-02-13 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
IL320607A (en) 2020-03-26 2025-07-01 Ramirez Fort Marigdalia Kaleth Ultraviolet radiation treatments
US11721428B2 (en) 2020-07-06 2023-08-08 Exini Diagnostics Ab Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions
AU2022361659A1 (en) 2021-10-08 2024-03-21 Exini Diagnostics Ab Systems and methods for automated identification and classification of lesions in local lymph and distant metastases
CN119791845B (zh) * 2025-01-03 2026-05-08 北京大学第一医院(北京大学第一临床医学院) 一种降低前列腺根治性切除术后切缘阳性的治疗设备

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098885A1 (en) * 2001-02-07 2002-12-12 Beth Israel Deaconess Medical Center Modified psma ligands and uses related thereto
JP4619651B2 (ja) * 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
ATE408712T1 (de) * 2003-01-10 2008-10-15 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
WO2005021709A2 (en) * 2003-05-29 2005-03-10 Diadexus, Inc. Cln101 antibodies
RU2450832C2 (ru) * 2006-10-25 2012-05-20 Конинклейке Филипс Электроникс Н.В. Контрастные вещества для детекции рака предстательной железы
WO2009046294A2 (en) * 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
EP2281004A4 (en) * 2008-04-14 2012-02-15 Proscan Rx Pharma Inc PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
WO2010065940A1 (en) * 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
EP3495000A1 (en) * 2009-02-17 2019-06-12 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
US8772226B2 (en) * 2009-03-17 2014-07-08 The Johns Hopkins University Methods and compositions for the detection of cancer

Also Published As

Publication number Publication date
JP2015513083A (ja) 2015-04-30
EP3064945A1 (en) 2016-09-07
EP2817629A2 (en) 2014-12-31
WO2013126147A3 (en) 2014-12-24
US20130225541A1 (en) 2013-08-29
WO2013126147A2 (en) 2013-08-29
HK1205788A1 (en) 2015-12-24
JP2019144254A (ja) 2019-08-29
US20180088120A1 (en) 2018-03-29
EP2817629A4 (en) 2016-01-13
CA2865282A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
JP2019144254A (ja) Ｐｓｍａ上昇により致死性前立腺癌が同定される
Donato et al. Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology
Baas et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Créhange et al. Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm
Kunikowska et al. [68 Ga] Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma
Sadeghi-Naini et al. Early prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral texture
HK1223847A1 (zh) 使用spect/ct分析进行癌症分期的方法
Jinghua et al. Clinical prospective study of Gallium 68 (68Ga)–labeled fibroblast-activation protein inhibitor PET/CT in the diagnosis of biliary tract carcinoma
Serban et al. Local recurrence management of extremity soft tissue sarcoma
Kwon et al. Prevalence and clinical significance of incidental 18F-fluoro-2-deoxyglucose uptake in prostate
Wang et al. Application of near-infrared fluorescence imaging in the accurate assessment of surgical margins during breast-conserving surgery
Abdel-Moety et al. SQSTM1 expression in hepatocellular carcinoma and relation to tumor recurrence after radiofrequency ablation
Brassell et al. Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer
Huang et al. HCC treated with immune checkpoint inhibitors: a hyper-enhanced rim on Sonazoid-CEUS Kupffer phase images is a predictor of tumor response
Dong et al. 18F-PSMA-1007 PET/CT-derived semi-quantitative parameters for risk stratification of newly diagnosed prostate cancer
Murata et al. SUVmax-based parameters of FDG-PET/CT reliably predict pathologic complete response after preoperative hyperthermo-chemoradiotherapy in rectal cancer
Nadebaum et al. Oligometastatic renal cell carcinoma with sarcomatoid differentiation demonstrating variable imaging phenotypes on 68Ga-PSMA and 18F-FDG PET/CT: A case report and review of the literature
Houvast et al. Prediction of biomarker expression on primary pancreatic ductal adenocarcinoma tissues using Fine-Needle biopsies: paving the way for a Patient-Tailored molecular imaging approach
Sengoz et al. Confirmation of PSMA expression measured on [68Ga] Ga-PSMA PET/CT by immunohistochemistry in prostate adenocarcinoma
Pełka et al. Imply on diagnosis and early prognosis of preoperative [68Ga] Ga-PSMA-11 PET/CT in patients with suspected brain tumours of glial origin
Jiang et al. Screening of radiotracer for diagnosis of colorectal cancer liver metastasis based on MACC1-SPON2
Kang et al. Sodium/iodide symporter expression in primary lung cancer and comparison with glucose transporter 1 expression
Safarian et al. The role of non-FDG agents in PET imaging of bladder cancer
Mouraviev et al. Use of 111In-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland
Kawamoto Therapy Response Imaging in Gastrointestinal Malignancy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190319

R150 Certificate of patent or registration of utility model

Ref document number: 6501524

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees